A practical reference on alpha-MSH analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-28. Anything still debated is marked as such rather than presented as settled.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
A cofactor is a non-protein chemical compound or metallic ion that is required for an enzyme's role as a catalyst. Cofactors can be considered "helper molecules" that assist in biochemical transformations. The rates at which these happen are characterized in an area of study called enzyme kinetics. Cofactors typically differ from ligands in that they often derive their function by remaining bound. Cofactors can be classified into two types: inorganic ions and complex organic molecules called coenzymes. Coenzymes are mainly derived from vitamins and other organic essential nutrients in small amounts (some definitions limit the use of the term "cofactor" for inorganic substances; both types are included here). Coenzymes are further divided into two types. The first is called a "prosthetic group", which consists of a coenzyme that is tightly (or even covalently and, therefore, permanently) bound to a protein. The second type of coenzymes are called "cosubstrates", and are transiently bound to the protein. Cosubstrates may be released from a protein at some point, and then rebind later. Both prosthetic groups and cosubstrates have the same function, which is to facilitate the reaction of enzymes and proteins. An inactive enzyme without the cofactor is called an apoenzyme, while the complete enzyme with cofactor is called a holoenzyme.
In biochemistry, a Ramachandran plot (also known as a Rama plot, a Ramachandran diagram or a [φ,ψ] plot), originally developed in 1963 by G. N. Ramachandran, C. Ramakrishnan, and V. Sasisekharan, is a way to visualize energetically allowed regions for backbone dihedral angles (also called as torsional angles, phi and psi angles) φ against ψ of amino acid residues in protein structure. The figure on the left illustrates the definition of the φ and ψ backbone dihedral angles (called φ and φ' by Ramachandran). The ω angle at the peptide bond is normally 180°, since the partial-double-bond character keeps the peptide bond planar. The figure in the top right shows the allowed φ,ψ backbone conformational regions from the Ramachandran et al. 1963 and 1968 hard-sphere calculations: full radius in solid outline, reduced radius in dashed, and relaxed tau (N-Cα-C) angle in dotted lines. Because dihedral angle values are circular and 0° is the same as 360°, the edges of the Ramachandran plot "wrap" right-to-left and bottom-to-top. For instance, the small strip of allowed values along the lower-left edge of the plot are a continuation of the large, extended-chain region at upper left.
=== Expansion to Asia and Europe === Chick-fil-A CEO Andrew Cathy announced in March 2023 that it planned to open restaurants in Asia and Europe by 2026, and was set to expand to five overseas markets by 2030. The Wall Street Journal reported that it was seeking countries with "stable economies, dense populations, and a demand for chicken".
Locals are called "Branches," regional groups are called "Districts," and national convention meets quadrennially. "Supreme Office" reported to be at 9 Seventh Street, New York in 1923. Reported to be in Brooklyn in the 1970s. Now at 399 Conklin Street - Suite 310 Farmingdale. Two Chicago-based German groups have merged into the WBF - the Mutual Benefit Aid Society and American Fraternal Insurance Society founded by Volga Germans. Two Jewish groups have merged into the WBF, the Free Sons of Israel in 2001 and the Workmen’s Circle in 2004. Among its activities were providing scholarships, donating to charities, and operating a convalescent home, summer camp, and home for the aged. It also offers "usual line of fraternal insurance and benevolence for its members" Had 384 lodges and 53,139 benefit members in 1923, 53,000 in 1965, 35,000 on December 31, 1978 and 15,000 in 1995.
Flucloxacillin, also known as floxacillin, is an antibiotic used to treat mastitis, skin infections, external ear infections, infections of leg ulcers, diabetic foot infections, and bone infections. It may be used together with other medications to treat pneumonia, and endocarditis. It may also be used prior to surgery to prevent Staphylococcus infections. It is not effective against methicillin-resistant Staphylococcus aureus (MRSA). It is taken by mouth or given by injection into a vein or muscle. Common side effects include an upset stomach. Other side effects may include muscle or joint pains, shortness of breath, and liver problems. It appears to be safe during pregnancy and breastfeeding. It should not be used in those who are allergic to penicillin. It is a narrow-spectrum beta-lactam antibiotic of the penicillin class. It is similar in effect to cloxacillin and dicloxacillin, being active against penicillinase forming bacteria. Flucloxacillin was patented in 1961. Flucloxacillin is not available in the United States.
Sources: en.wikipedia.org
As mentioned above, the naturally occurring nucleotides (nucleoside-3'- or 5'-phosphates) and their phosphodiester analogs are insufficiently reactive to afford an expeditious synthetic preparation of oligonucleotides in high yields. The selectivity and the rate of the formation of internucleosidic linkages is dramatically improved by using 3'-O-(N,N-diisopropyl phosphoramidite) derivatives of nucleosides (nucleoside phosphoramidites) that serve as building blocks in phosphite triester methodology. To prevent undesired side reactions, all other functional groups present in nucleosides have to be rendered unreactive (protected) by attaching protecting groups. Upon the completion of the oligonucleotide chain assembly, all the protecting groups are removed to yield the desired oligonucleotides. Below, the protecting groups currently used in commercially available and most common nucleoside phosphoramidite building blocks are briefly reviewed:
=== Pharmacodynamics === Citalopram contains two pharmacodynamically distinct enantiomers: (S)-citalopram (escitalopram) and (R)-citalopram. (S)-citalopram is a highly selective serotonin reuptake inhibitor and is thought to be responsible for most of the SRI activity of citalopram. (R)-citalopram, by comparison, is a 20-fold less potent SERT inhibitor and antagonizes the actions of (S)-citalopram at this site. The mechanism of antagonism is uncertain, but may involve kinetic interactions between the two; it has been proposed that the long-lasting inhibited state of SERT induced by (S)-citalopram may be attenuated by (R)-citalopram binding. Citalopram has a ~6-fold higher affinity for H1 histamine receptors than (S)-citalopram (Ki = 257nM vs 1500nM), though the clinical significance of this difference is unknown. Both citalopram and escitalopram have similar affinities for the σ1 receptor (Ki = 50nM).
== Adverse effects == During clinical trials, the most common adverse effects of trastuzumab emtansine were fatigue, nausea, musculoskeletal pain, thrombocytopenia (low platelet counts), headache, increased liver enzyme levels, and constipation. Severe adverse events identified during the EMILIA trial included hepatotoxicity (liver damage), including rare cases of liver failure, hepatic encephalopathy, and nodular regenerative hyperplasia; heart damage (dysfunction of the left ventricle); interstitial lung disease, including acute interstitial pneumonitis; thrombocytopenia; and peripheral neuropathy. Overall, trastuzumab emtansine was better tolerated than the control treatment, a combination of lapatinib (Tykerb) and capecitabine (Xeloda), with 43% of patients in the trastuzumab emtansine group experiencing severe toxic effects, versus 59% of those who received lapatinib/capecitabine; furthermore, fewer patients had to stop treatment due to adverse effects than with lapatinib or capecitabine. Anemia, low platelet counts, and peripheral neuropathy were more common among patients who received trastuzumab emtansine, whereas heart damage and gastrointestinal effects, such as vomiting, diarrhea, and stomatitis, were more common with lapatinib/capecitabine. In the United States, trastuzumab emtansine carries black box warnings for liver toxicity, heart damage (reduction in left ventricular ejection fraction), and fetal harm if given to pregnant women.
To cataplerotically remove oxaloacetate from the citric cycle, malate can be transported from the mitochondrion into the cytoplasm, decreasing the amount of oxaloacetate that can be regenerated. Furthermore, citric acid intermediates are constantly used to form a variety of substances such as the purines, pyrimidines and porphyrins.
Sources: en.wikipedia.org
metabolism The complete set of chemical reactions which sustain and account for the basic processes of life in all living cells, especially those involving: 1) the conversion of energy from food into energy available for cellular activities; 2) the breakdown of food into simpler compounds which can then be used as substrates to build complex biomolecules such as proteins, lipids, and nucleic acids; and 3) the degradation and excretion of toxins, byproducts, and other unusable compounds known as metabolic wastes. In a broader sense the term may include all chemical reactions occurring in living organisms, even those which are not strictly necessary for life but instead serve accessory functions. Many specific cellular activities are accomplished by metabolic pathways in which one chemical is ultimately transformed through a stepwise series of reactions into another chemical, with each reaction catalyzed by a specific enzyme. Most metabolic reactions can be subclassified as catabolic or anabolic.
Historically, Romanian researchers and inventors have made notable contributions to several fields. In the history of flight, Traian Vuia built the first aeroplane to take off under its own power and Aurel Vlaicu built and flew some of the earliest successful aircraft, while Henri Coandă discovered the Coandă effect of fluidics. Victor Babeș discovered more than 50 types of bacteria; biologist Nicolae Paulescu developed an extract of the pancreas and showed that it lowers blood sugar in diabetic dogs, thus being significant in the history of insulin; while Emil Palade received the Nobel Prize for his contributions to cell biology. Lazăr Edeleanu was the first chemist to synthesise amphetamine, and he also invented the procedure of separating valuable petroleum components with selective solvents. During the 1990s and 2000s, the development of research was hampered by several factors, including corruption, low funding, and a considerable brain drain. In recent years, Romania has ranked the lowest or second-lowest in the EU by research and development spending as a percentage of GDP, standing at roughly 0.5% in 2016 and 2017, substantially below the EU average of just over 2%. The country joined the European Space Agency (ESA) in 2011, and CERN in 2016. In 2018, however, Romania lost its voting rights in the ESA due to a failure to pay €56.8 million in membership contributions to the agency. In the early 2010s, the situation for science in Romania was characterised as "rapidly improving" albeit from a low base.
=== Clinical trials === In 2020, there were 197 clinical trials related to varied therapies and biomarkers for HD listed as either underway, recruiting or newly completed. Compounds trialed that have failed to prevent or slow the progression of HD include remacemide, coenzyme Q10, riluzole, creatine, minocycline, ethyl-EPA, phenylbutyrate and dimebon.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.